Melanoma and immunotherapy bridge 2015
Vashisht Gopal Yennu Nanda, Weiyi Peng, Patrick Hwu et al. · Journal of Translational Medicine · 2016
Background: The PI3K/AKT/mTOR signaling pathway has been implicated in multiple cancers, and as a regulator of many key oncogenic processes.Our studies implicate a role for this pathway in resistance to both targeted and immune therapies for melanoma.Materials and methods: Melanoma cell lines and clinical specimens were utilized to study the significance and functional consequences of the PI3K/AKT/mTOR pathway.Analyses of clinical specimens were performed under institution review board-approved protocols.Results: Pilot whole genome expression profiling and synthetic lethality screens implicated oxidative phosphorylation (OxPhos) in resistance to BRAF and MEK inhibitors in BRAF-mutant human melanoma cell lines.Characterization of panels of human cell lines with de novo or acquired resistance to MAPK pathway inhibitors demonstrated that ~50 % of the cell lines exhibited a high OxPhos phenotype.The presence of high OxPhos correlated with increased expression of PGC1-alpha and with sensitivity to combined inhibition of the MAPK pathway and mTORC1/2.mTORC1/2 inhibition caused cytoplasmic sequestration of MITF and subsequent decreased expression of MITF-regulated genes, including PGC1-alpha.In vitro testing demonstrated that a direct OxPhos inhibitor similarly achieved growth inhibition and apoptosis in some human melanoma cell lines with high OxPhos.Further, the OxPhos inhibitor abrogated the growth of inhibitor-resistant BRAF mutant human melanoma cell lines in vivo.Activation of the PI3K/AKT/mTOR pathway by loss of PTEN was also shown to promote resistance to T cell mediated cell killing in vitro and in vivo.Loss of PTEN correlated with decreased CD8 cell infiltrates in clinical specimens and increased expression of immunosuppressive cytokines.While pan-PI3K inhibitors inhibited immune cell viability and function, isoform-selective inhibitors did not significantly affect immune function and they produced synergy with immunotherapy.Conclusions: The PI3K/AKT/mTOR signaling pathway is an important regulator of key cellular processes in melanoma, and should be considered as a candidate combinatorial partner for both targeted and immune therapies.
Cited by 22 works. doi:10.1186/s12967-016-0791-2 Open-access PDF
Authors
- Vashisht Gopal Yennu Nanda
- Weiyi Peng
- Patrick Hwu
- Michael A. Davies
- Gennaro Ciliberto
- Luigi Fattore
- Debora Malpicci
- Luigi Aurisicchio
- Paolo A. Ascierto
- Carlo Maria Croce
- Rita Mancini
- Stefani Spranger
- Thomas Frank Gajewski
- Yangyang Wang
- Soldano Ferrone
- Claire Vanpouille‐Box
- Erik Wennerberg
- Karsten A. Pilones
- Silvia Chiara Formenti
- Sandra Demaria
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- The blockade of immune checkpoints in cancer immunotherapy
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Enhancement of Antitumor Immunity by CTLA-4 Blockade
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome